REQUEST A DEMO
Total
USD $0.00
Search more companies

OBI Pharma, Inc. (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: OBI Pharma, Inc. Profile Updated: February 22, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English & Chinese Download a sample report

Optimer Biotechnology, Inc. (OBI) is a biotech company was formed in Taiwan in 2002. At beginning, it’s structured as a wholly owned subsidiary of Optimer Pharmaceuticals Inc. (OPTR) in San Diego, CA, USA. In November, 2009, it was spinning off from OPTR, forming a new management team with a mission to develop novel therapeutic agents for diseases that are currently lacking treatment options. The initial therapeutic focus will be cancer and osteoarthritis. OBI is positioned as a new product development company striving to improve health and quality of life through innovative and cost effective medicine.

Headquarters
19F, No.3, Yuan Qu Street, Nangang Software
Taipei City; Taipei City;

Contact Details: Purchase the OBI Pharma, Inc. report to view the information.

Website: http://www.obipharma.com

Basic Information
Total Employees:
Purchase the OBI Pharma, Inc. report to view the information.
Outstanding Shares:
Purchase the OBI Pharma, Inc. report to view the information.
Financial Auditors:
Purchase the OBI Pharma, Inc. report to view the information.
Incorporation Date:
April 29, 2002
Key Executives
Purchase this report to view the information.
Chairman
Ownership Details
Purchase this report to view the information.
11.23%
Purchase this report to view the information.
1.42%
Purchase this report to view the information.
Purchase this report to view the information.
Purchase this report to view the information.
Subsidiaries
Obi Pharma Australiapty.Ltd. (Australia)
100%
Obi Pharma Usa Inc. (United States)
100%
Odeon Therapeutics (Cayman) Limited (United Kingdom)
77.42%
Company Performance
Financial values in the chart are available after OBI Pharma, Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Net sales revenue
450.19%
Total operating revenue
N/A
Operating profit (EBIT)
-15.34%
EBITDA
-42.9%
Net Profit (Loss) for the Period
43.57%
Total assets
-12.82%
Total equity
-16.32%
Operating Profit Margin (ROS)
27896.64%
Net Profit Margin
26481.1%
Return on Equity (ROE)
6.14%
Debt to Equity Ratio
8.79%
Quick Ratio
-3.12%
Cash Ratio
-13.03%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?